Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer. Nat Rev Dis Primers. 2016 Aug 25;2:16061.
DOI: 10.1038/nrdp.2016.61
Prat J; FIGO Committee on Gynecologic Oncology. Staging Classification for Cancer of the Ovary, Fallopian Tube, and Peritoneum: Abridged Republication of Guidelines From the International Federation of Gynecology and Obstetrics (FIGO).Obstet Gynecol. 2015 Jul;126(1):171-4.
DOI: 10.1097/AOG.0000000000000917
Köbel M, Kang EY. The Evolution of Ovarian Carcinoma Subclassification. Cancers (Basel). 2022 Jan 14;14(2):416.
DOI: 10.3390/cancers14020416
Hidalgo JJ, Ros F, Aubá M, Errasti T , Olartecoechea B , Ruiz-Zambrana Á , et al. Prospective external validation of IOTA three-step strategy for characterizing and classifying adnexal masses and retrospective assessment of alternative two-step strategy using simple-rules risk. Ultrasound Obstet Gynecol 2019;53(5):693-700.
DOI: 10.1002/uog.20163
Kaijser J, Sayasneh A, Van Hoorde K, Ghaem-Maghami S, Bourne T, Timmerman D, et al. Presurgical diagnosis of adnexal tumours using mathematical models and scoring systems: A systematic review and meta-analysis. Hum Reprod Update 2014;20:449-462
DOI: 10.1093/humupd/dmt059
Cooper BC, Sood AK, Davis CS, Ritchie JM, Sorosky JI, Anderson B, Buller RE. Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer. Obstet Gynecol. 2002 Jul;100(1):59-64.
DOI: 10.1097/00006250-200207000-00010
Nolen B, Velikokhatnaya L, Marrangoni A, De Geest K, Lomakin A, Bast RC Jr, Lokshin A. Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol. 2010 Jun;117(3):440-5.
DOI: 10.1016/j.ygyno.2010.02.005
Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, et al. PLCO Project Team. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011 Jun 8;305(22):2295-303.
DOI: 10.1001/jama.2011.766
Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2016 Mar 5;387(10022):945-56.
DOI: 10.1016/S0140-6736(15)01224-6
Angioli R, Plotti F, Capriglione S, Aloisi A, Montera R, Luvero D, et al. Can the preoperative HE4 level predict optimal cytoreduction in patients with advanced ovarian carcinoma? Gynecol Oncol. 2013 Mar;128(3):579-83
DOI: 10.1016/j.ygyno.2012.11.040
Suri A, Perumal V, Ammalli P, Suryan V, Bansal SK. Diagnostic measures comparison for ovarian malignancy risk in Epithelial ovarian cancer patients: a meta-analysis. Sci Rep. 2021 Aug 27;11(1):17308.
DOI: 10.1038/s41598-021-96552-9
Fotopoulou C, Hall M, Cruickshank D, Gabra H, Ganesan Raji, Hughes C, et al.British Gynaecological Cancer Society (BGCS) Epithelial Ovarian / Fallopian Tube / Primary Peritoneal Cancer Guidelines: Recommendations for practice. Eur J Obstet Gynecol Reprod Biol 2017;213:123-139
DOI: 10.1016/j.ejogrb.2017.04.016
Whitehouse C, Solomon E. Current Status of the Molecular Characterization of the Ovarian Cancer Antigen CA125 and Implications for Its Use in Clinical Screening. Gynecologic Oncology 2003;88, S152–S157.
DOI: 10.1006/gyno.2002.6708
Lennox GK, Eiriksson LR, Reade CJ, Leung F, Mojtahedi G, Atenafu EG, et al. Effectiveness of the risk of malignancy index and the risk of ovarian malignancy algorithm in a cohort of women with ovarian cancer: does histotype and stage matter?. Int J Gynecol Cancer. 2015 Jun;25(5):809-14.
DOI: 10.1097/IGC.0000000000000442
Ikeda Y, Hasegawa K, Kurosaki A, Miyara A, Hanaoka T, Shintani D, et al. The Risk of Ovarian Malignancy Algorithm (ROMA) as a Predictive Marker of Peritoneal Dissemination in Epithelial Ovarian Cancer Patients. Oncol Res Treat. 2015;38(6):276-81
DOI: 10.1159/000430858
Steffensen KD, Waldstrøm M, Brandslund I, Petzold M, Jakobsen A. The prognostic and predictive value of combined HE4 and CA-125 in ovarian cancer patients. Int J Gynecol Cancer. 2012 Nov;22(9):1474-82
DOI: 10.1097/IGC.0b013e3182681cfd
Dodge JE, Covens AL, Lacchetti C, Elit LM, Le T, Devries-Aboud M, Fung-Kee-Fung M; Gynecology Cancer Disease Site Group. Preoperative identification of a suspicious adnexal mass: a systematic review and meta-analysis. Gynecol Oncol 2012; 126:157..
DOI: 10.1016/j.ygyno.2012.03.048
Glickman A, Paredes P, Carreras-Diéguez N, Niñerola-Baizán A, Gaba L, Pahisa J, et al. Evaluation of patients with advanced epithelial ovarian cancer before primary treatment: correlation between tumour burden assessed by [18F]FDG PET/CT volumetric parameters and tumour markers HE4 and CA125. Eur Radiol. 2021 Sep 29.
DOI: 10.1007/s00330-021-08305-x
Kang S, Park SY.To predict or not to predict? The dilemma of predicting the risk of suboptimal cytoreduction in ovarian cancer. Ann Oncol. 2011 Dec;22 Suppl 8:viii23-viii28
DOI: 10.1093/annonc/mdr530
Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Le Moigne-Amrani A, Dietrich-Neto F; ENOXACAN II Investigators. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. 2002 Mar 28;346(13):975-80
DOI: 10.1056/NEJMoa012385
Marques de Marino P, Rial Horcajo R, Garcia Grandal T, Sanchez Hervas L, Serrano Hernando FJ, Herraiz Martinez MA, Coronado Martin PJ. Thromboprophylaxis in gynecologic cancer surgery: Is extended prophylaxis with low molecular weight heparin justified? Eur J Obstet Gynecol Reprod Biol. 2018 Nov;230:90-95.
DOI: 10.1016/j.ejogrb.2018.09.028
Verleye L, Ottevanger PB, van der Graaf W, Reed NS, Vergote I; Gynaecological Cancer Group (GCG) of European Organisation for Research and Treatment of Cancer (EORTC). EORTC-GCG process quality indicators for ovarian cancer surgery. Eur J Cancer. 2009 Mar;45(4):517-26
DOI: 10.1016/j.ejca.2008.09.031
Prat J; FIGO Committee on Gynecologic Oncology. Staging Classification for Cancer of the Ovary, Fallopian Tube, and Peritoneum: Abridged Republication of Guidelines From the International Federation of Gynecology and Obstetrics (FIGO). Obstet Gynecol. 2015 Jul;126(1):171-4.
DOI: 10.1097/AOG.0000000000000917
Oncoguía SEGO: Cancer Epitelial de ovario, trompa y peritoneo 2014. Guías de práctica clínica en cáncer ginecológico y mamario. Publicaciones SEGO, Octubre 2014
Falcetta FS, Lawrie TA, Medeiros LR, da Rosa MI, Edelweiss MI, Stein AT, et al. Laparoscopy versus laparotomy for FIGO stage I ovarian cancer. Cochrane Database Syst Rev 2016;10:CD005344.
DOI: 10.1002/14651858.CD005344.pub4
Melamed A, Keating NL, Clemmer JT, Bregar AJ, Wright JD, Boruta DM. Laparoscopic staging for apparent stage I epithelial ovarian cancer. Am J Obstet Gynecol 2017;216(1):50.e1-50.e1
DOI: 10.1016/j.ajog.2016.08.030
Lago V, Minig L, Fotopoulou C. Incidence of lymph node metastases in apparent early-stage low- grade epithelial ovarian cancer: A comprehensive review. Int J Gynecol Cancer 2016;26(8):1407-14.
DOI: 10.1097/IGC.0000000000000787
Bizzarri N, du Bois A, Fruscio R, De Felice F, De Iaco P, Casarin J, et al. Is there any therapeutic role of pelvic and para-aortic lymphadenectomy in apparent early stage epithelial ovarian cancer? Gynecol Oncol 2021;160(1):56-63
DOI: 10.1016/j.ygyno.2020.10.028
Coronado PJ, Fasero M, Vidart JA. Supervivencia y tratamiento de los tumores de bajo potencial maligno del ovario. Toko-Gin Pract 2004;63(2):127-40
Cusidó M, Balagueró L, Hernandez G, Falcón O, Rodríguez-Escudero FJ, Vargas JA, Vidart JA, Zamora L, Monera M, Alonso A; Section of Gynecologic Oncology and Breast Pathology of Spanish Federation of Gynecologic Oncology (SEGO). Results of the national survey of borderline ovarian tumors in Spain. Gynecol Oncol. 2007 Mar;104(3):617-22.
DOI: 10.1016/j.ygyno.2006.10.001
Vergote I, Gonzalez-Martin A, Lorusso D, Gourley C, Mirza MR, Kurtz JE, et al; participants of the 6th Gynecologic Cancer InterGroup (GCIG) Ovarian Cancer Consensus Conference on Clinical Research. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup. Lancet Oncol. 2022 Aug;23(8):e374-e384.
Zivanovic O, Sima CS, Iasonos A, Hoskins WJ, Pingle PR, Leitao MM Jr, Sonoda Y, Abu-Rustum NR, Barakat RR, Chi DS.The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper abdomen cephalad to the greater omentum. Gynecol Oncol. 2010 Mar;116(3):351-7.
DOI: 10.1016/j.ygyno.2009.11.022
Fagotti A, Ferrandina G, Fanfani F, Ercoli A, Lorusso D, Rossi M, Scambia G. A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study. Ann Surg Oncol. 2006 Aug;13(8):1156-61. Epub 2006 Jun 21.
DOI: 10.1245/ASO.2006.08.021
Petrillo M, Vizzielli G, Fanfani F, et al. Definition of a dynamic laparoscopic model for the prediction of incomplete cytoreduction in advanced epithelial ovarian cancer: Proof of a concept. Gynecol Oncol 139(1):5-9, 2015.
Fagotti A, Vizzielli G, De Iaco P, Surico D, Buda A, Mandato VD, et al. A multicentric trial(Olympia-MITO 13) on the accuracy of laparoscopy to assess peritoneal spread in ovarian cancer. Am J Obstet Gynecol. 2013 Nov;209(5):462.e1-462.e11
DOI: 10.1016/j.ajog.2013.07.016
Vizzielli G, Costantini B, Tortorella L, Pitruzzella I, Gallotta V, Fanfani F, et al. A laparoscopic risk-adjusted model to predict major complications after primary debulking surgery in ovarian cancer: A single-institution assessment. Gynecol Oncol. 2016 Jul;142(1):19-24.
DOI: 10.1016/j.ygyno.2016.04.020
Harter P, Sehouli J, Lorusso D, Reuss A, Vergote I, Marth C, et al. A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms. N Engl J Med. 2019 Feb 28;380(9):822-832.
DOI: 10.1056/NEJMoa1808424
Dahm-Kähler P, Palmqvist C, Staf C, Holmberg E, Johannesson L. Centralized primary care of advanced ovarian cancer improves complete cytoreduction and survival - A population-based cohort study. Gynecol Oncol 2016;142:211-6.
DOI: 10.1016/j.ygyno.2016.05.025
Vergote I. Randomized trial comparing primary debulking surgery with neoadjuvant chemotherapy followed by interval debulking in stage IIIc‐IV ovarian, fallopian tube and peritoneal cancer. Presented in IGCS Meeting, Bangkok. October 25th 2008.
Bristow RE, Eisenhauer EL, Santillan A, Chi DS. Delaying the primary surgical effort for advanced ovarian cancer: A systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecol Oncol. 2007; 104: 480-90.
DOI: 10.1016/j.ygyno.2006.11.002
Kuhn W, Rutke S, Späthe K, Schmalfeldt B, Florack G, von Hundelshausen B, et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics stage IIIC ovarian carcinoma. Cancer 2001; 92:2585–91.
DOI: 10.1002/1097-0142(20011115)92:10<2585::AID-CNCR1611>3.0.CO;2-#
Loizzi V, Cormio G, Resta L, Rossi CA, DiGilio AR, Cuccovillo A, et al. Neoadjuvant chemotherapy in advanced ovarian cancer: a case–control study. Int J Gynecol Cancer 2005;15: 217–23.
DOI: 10.1136/ijgc-00009577-200503000-00005
Chan YM, Ng TY, Ngan HYS,Wong LC. Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study. Gynecol Oncol 2002;88: 9–16.
DOI: 10.1006/gyno.2002.6849
Fanfani F, Ferrandina G, Corrado G, Fagotti A, Zakut HV, Mancuso S, et al. Impact of interval debulking surgery on clinical outcome in primary unresectable FIGO Stage IIIc ovarian cancer patients. Oncology 2003;65:316–22
DOI: 10.1159/000074644
Morice P, Dubernard G, Rey A, Atallah D, Pautier P, Pomel C, et al. Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer. J Am Coll Surg 2003;197: 955–63.
DOI: 10.1016/j.jamcollsurg.2003.06.004
Giannopoulos T, Butler-Manuel S, Taylor A, Ngeh N, Thomas H. Clinical outcomes of neoadjuvant chemotherapy and primary debulking in advanced ovarian carcinoma. Eur J Gynaecol Oncol 2006; 27:25–8.
Eltabbakh GH, Mount SL, Beatty B, Simmons-Arnold L, Cooper K, Morgan A. Factors associated with cytoreducibility among women with ovarian carcinoma. Gynecol Oncol 2004;95:377–83.
DOI: 10.1016/j.ygyno.2004.07.045
Brockbank EC, Ind TEJ, Barton DPJ, Sheperd JH, Gore ME, A'hern R, et al. Preoperative predictors of suboptimal primary surgical cytoreduction in women with clinical evidence of advanced primary epithelial ovarian cancer. Int J Gynecol Cancer 2004;14:42–50.
DOI: 10.1136/ijgc-00009577-200401000-00005
Dhanda S, Thakur M, Kerkar R, Jagmohan P. Diffusion-weighted imaging of gynecologic tumors: diagnostic pearls and potential pitfalls. Radiographics. 2014 Sep-Oct;34(5):1393-416.
DOI: 10.1148/rg.345130131
Aletti GD, Dowdy SC, Podratz KC, Cliby WA. Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer. Am J Obstet Gynecol. 2007 Dec;197(6):676.e1-7.
DOI: 10.1016/j.ajog.2007.10.495
Aletti GD, Dowdy SC, Gostout BS, Jones MB, Stanhope RC, Wilson TO, Podratz KC, Cliby WA. Quality improvement in the surgical approach to advanced ovarian cancer: the Mayo Clinic experience. J Am Coll Surg. 2009 Apr;208(4):614-20.
DOI: 10.1016/j.jamcollsurg.2009.01.006
Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015 Jul 18;386(9990):249-57.
DOI: 10.1016/S0140-6736(14)62223-6
Onda T, Satoh T, Ogawa G, Saito T, Kasamatsu T, Nakanishi T, et al; Japan Clinical Oncology Group. Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial. Eur J Cancer. 2020 May;130:114-125.
DOI: 10.1016/j.ejca.2020.02.020
Fagotti A, Ferrandina G, Vizzielli G, Fanfani F, Gallotta V, Chiantera V. Phase III randomized clinical trial comparing primary surgery versus neoadjuvant chemotherapy inadvanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome. Eur J Cancer. 2016 May;59:22-33.
DOI: 10.1016/j.ejca.2016.01.017
Reuss A, du Bois A, Harter P, Fotopoulou C, Sehouli J, Aletti G, et al. TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7). Int J Gynecol Cancer. 2019 Oct;29(8):1327-1331.
DOI: 10.1136/ijgc-2019-000682
Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. Gynecol Oncol. 2016 Oct;143(1):3-15.
DOI: 10.1016/j.ygyno.2016.05.022
Morice P, Leblanc E, Rey A, Baron M, Querleu D, Blanchot J, Duvillard P, Lhomme C, Castaigne D, Classe JM, Bonnier P; GCCLCC and SFOG. Conservative treatment in epithelial ovarian cancer: results of a multicentre study of the GCCLCC (Groupe des Chirurgiens de Centre de Lutte Contre le Cancer) and SFOG (Societe Francaise d'Oncologie Gynecologique). Hum Reprod. 2005; 20:1379-85.
DOI: 10.1093/humrep/deh777
Morice P, Wicart-Poque F, Rey A, El-Hassan J, Pautier P, Lhomme C, de Crevosier R, Haie-Meder C, Duvillard P, Castaigne D. Results of conservative treatment in epithelial ovarian carcinoma. Results of conservative treatment in epithelial ovarian carcinoma. Cancer. 2001; 92:2412-8.
DOI: 10.1002/1097-0142(20011101)92:9<2412::AID-CNCR1590>3.0.CO;2-7
Bentivegna E, Gouy S, Maulard A, Pautier P, Leary A, Colombo N, et al. Fertility-sparing surgery in epitelial ovarian cancer: A systematic review of oncological issues. Ann Oncol 2016;27(11):1994-2004.
DOI: 10.1093/annonc/mdw311
Schilder JM, Thompson AM, DePriest PD, Ueland FR, Cibull ML, Kryscio RJ, Modesitt SC, Lu KH, Geisler JP, Higgins RV, Magtibay PM, Cohn DE, Powell MA, Chu C, Stehman FB, van Nagell J. Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecol Oncol. 2002; 87:1-7.
DOI: 10.1006/gyno.2002.6805
Levine J, Canada A, Stern CJ. Fertility Preservation in Adolescents and Young Adults With Cancer. J Clin Oncol. 2010 Nov 10;28(32):4831-41
DOI: 10.1200/JCO.2009.22.8312
Ghezzi F, Cromi A, Siesto G, Serati M, Zaffaroni E, Bolis P. Laparoscopy staging of early ovarian cancer: our experience and review of the literature. Int J Gynecol Cancer. 2009 Dec;19 Suppl 2:S7-S13.
DOI: 10.1111/IGC.0b013e3181bf82f3
Falcetta FS, Lawrie TA, Medeiros LR, da Rosa MI, Edelweiss MI, Stein AT, Zelmanowicz A, Moraes AB, Zanini RR, Rosa DD. Laparoscopy versus laparotomy for FIGO stage I ovarian cancer. Cochrane Database Syst Rev. 2016 Oct 13;10(10):CD005344.
DOI: 10.1002/14651858.CD005344.pub4
Vergote I, Marquette S, Amant F, Berteloot P, Neven P. Port-site metastases after open laparoscopy: a study in 173 patients with advanced ovarian carcinoma. Int J Gynecol Cancer 2005 Sep-Oct;15(5):776-9
DOI: 10.1136/ijgc-00009577-200509000-00010
Coronado Martín PJ. Robotic surgery in gynecology: is it the future?. An R Acad Nac Med (Madr). 2011;128(4):679-92; discussion 692-4. Spanish.
Cantrell LA, Mendivil A, Gehrig PA, Boggess JF. Survival outcomes for women undergoing type III robotic radical hysterectomy for cervical cancer: a 3-year experience. Gynecol Oncol. 2010 May;117(2):260-5. Epub 2010 Feb 13.
DOI: 10.1016/j.ygyno.2010.01.012
Coronado PJ, Fasero M, Magrina JF, Herraiz MA, Vidart JA. Comparison of perioperative outcomes and cost between robotic-assisted and conventional laparoscopy for transperitoneal infrarenal para-aortic lymphadenectomy (TIPAL). J Minim Invasive Gynecol. 2014 Jul-Aug;21(4):674-81.
DOI: 10.1016/j.jmig.2014.01.023
Coronado PJ, Herraiz MA, Magrina JF, Fasero M, Vidart JA. Comparison of perioperative outcomes and cost of robotic-assisted laparoscopy, laparoscopy and laparotomy for endometrial cancer. Eur J Obstet Gynecol Reprod Biol. 2012 Dec;165(2):289-94.
DOI: 10.1016/j.ejogrb.2012.07.006
Gallotta V, Certelli C, Oliva R, Rosati A, Federico A, Loverro M, Lodoli C, Foschi N, Lathouras K, Fagotti A, Scambia G. Robotic surgery in ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2023 Aug;90:102391.
DOI: 10.1016/j.bpobgyn.2023.102391
Minig L, Padilla Iserte P, Zorrero C, Zanagnolo V. Robotic Surgery in Women With Ovarian Cancer: Surgical Technique and Evidence of Clinical Outcomes. J Minim Invasive Gynecol. 2016 Mar-Apr;23(3):309-16.
DOI: 10.1016/j.jmig.2015.10.014
Magrina JF, Zanagnolo V, Noble BN, Kho RM, Magtibay P. Robotic approach for ovarian cancer: perioperative and survival results and comparison with laparoscopy and laparotomy. Gynecol Oncol 2011;121:100-5.
DOI: 10.1016/j.ygyno.2010.11.045
Feuer GA, Lakhi N, Barker J, Salmieri S, Burrell M. Perioperative and clinical outcomes in the management of epithelial ovarian cancer using a robotic or abdominal approach. Gynecol Oncol 2013;131:520-4.
DOI: 10.1016/j.ygyno.2013.09.022
V. Psomiadou, A. Prodromidou, A. Fotiou, S. Lekka, C. Iavazzo. Robotic interval debulking surgery for advanced epithelial ovarian cancer: current challenge or future direction? A systematic review. J Robot Surg, 15 (2) (2021 Apr), pp. 155-163, 10.1007/s11701-020-01155-7
DOI: 10.1007/s11701-020-01155-7
Petrillo M, Fagotti A, Ferrandina G, Fanfani F, Costantini B, Vizzielli G, et al. Ovarian cancer patients with localized relapse: clinical outcome and prognostic factors. Gynecol Oncol 2013;131:36-41.
DOI: 10.1016/j.ygyno.2013.06.020
Magrina JF, Cetta RL, Chang YH, Guevara G, Magtibay PM. Analysis of secondary cytoreduction for recurrent ovarian cancer by robotics, laparoscopy and laparotomy. Gynecol Oncol 2013;129:336-40.
DOI: 10.1016/j.ygyno.2013.01.015
Escobar PF, Levinson KL, Magrina J, Martino MA, Barakat RR, Fader AN, et al. Feasibility and perioperative outcomes of robotic-assisted surgery in the management of recurrent ovarian cancer: A multi-institutional study. Gynecol Oncol 2014;134:253-6.
DOI: 10.1016/j.ygyno.2014.05.007
Número de descargas:
610
Número de visitas:
51
Citas:
0
